Selected article for: "epidemic diarrhea and PEDV infection"

Author: Yuan, Chen; Huang, Xintong; Zhai, Ruiyu; Ma, Yichao; Xu, Anyuan; Zhang, Penghao; Yang, Qian
Title: In Vitro Antiviral Activities of Salinomycin on Porcine Epidemic Diarrhea Virus
  • Cord-id: 8a9nb5jx
  • Document date: 2021_3_30
  • ID: 8a9nb5jx
    Snippet: Porcine epidemic diarrhea virus (PEDV), an enteropathogenic coronavirus, has catastrophic impacts on the global pig industry. Owing to the lack of effective vaccines and specific therapeutic options for PEDV, it is pertinent to develop new and available antivirals. This study identified, for the first time, a salinomycin that actively inhibited PEDV replication in Vero cells in a dose-dependent manner. Furthermore, salinomycin significantly inhibited PEDV infection by suppressing the entry and p
    Document: Porcine epidemic diarrhea virus (PEDV), an enteropathogenic coronavirus, has catastrophic impacts on the global pig industry. Owing to the lack of effective vaccines and specific therapeutic options for PEDV, it is pertinent to develop new and available antivirals. This study identified, for the first time, a salinomycin that actively inhibited PEDV replication in Vero cells in a dose-dependent manner. Furthermore, salinomycin significantly inhibited PEDV infection by suppressing the entry and post-entry of PEDV in Vero cells. It did not directly interact with or inactivate PEDV particles, but it significantly ameliorated the activation of Erk1/2, JNK and p38MAPK signaling pathways that are associated with PEDV infection. This implied that salinomycin inhibits PEDV replication by altering MAPK pathway activation. Notably, the PEDV induced increase in reactive oxidative species (ROS) was not decreased, indicating that salinomycin suppresses PEDV replication through a pathway that is an independent pathway of viral-induced ROS. Therefore, salinomycin is a potential drug that can be used for treating PEDV infection.

    Search related documents:
    Co phrase search for related documents
    • acute sars cov respiratory syndrome coronavirus and addition time analysis: 1
    • acute sars cov respiratory syndrome coronavirus and log reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • acute sars cov respiratory syndrome coronavirus and lysis buffer: 1, 2, 3
    • addition time and log reduction: 1